Intermediate Effect Variants in HCM: Integration into Clinical Practice and Family Screening

Walsh et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69fbb049aaff9451631ac0fd — DOI: https://doi.org/10.1161/circulationaha.125.077435

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings· 2025 · 37 citations
2. Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy· 2024 · 21 citations
3. 2023 ESC Guidelines for the management of cardiomyopathies· 2023 · 2,237 citations
4. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants· 2025 · 14 citations
5. Family Screening in Hypertrophic Cardiomyopathy· 2024 · 12 citations